single5MG
Semaglutide
5MG Protocol
Semaglutide 5MG
Injection Freq.
Inject once weekly
Cycle Sched.
Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation
Reconstitution
2.0 mL BAC water
Significant weight loss (~10–15% mean in trials with lifestyle support)
Improved glycemic control via glucose-dependent insulin secretion
Reduced appetite and food intake via CNS GLP-1 signaling
Cardiovascular outcome benefits reported (reduced MACE risk)
Once-weekly dosing convenience
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 250 mcg (0.25 mg) | 10 |
| 2 | Weeks 5–8 | 500 mcg (0.5 mg) | 20 |
| 3 | Weeks 9–12 | 1000 mcg (1.0 mg) | 40 |
| 4 | Weeks 13–16 | 1700 mcg (1.7 mg) | 68 |
| 5 | Weeks 1+ | 2400 mcg (2.4 mg) | 96 |
Inject once weekly
Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation
Semaglutide (semaglutide) is described as a long-acting GLP-1 receptor agonist used for weight management and glycemic support. The protocol explains that GLP-1 receptor activation reduces appetite and food intake via central nervous system signaling, slows gastric emptying to reduce post-meal glucose excursions, and improves glycemic control by increasing insulin secretion only when glucose is elevated while reducing glucagon. The page highlights why this can be done weekly: semaglutide’s design improves albumin binding and resists DPP-4 breakdown, producing an approximate 7-day half-life. Clinical outcomes summarized include mean weight reductions around 10–15% at the standard weekly maintenance dose when combined with lifestyle intervention, alongside improvements in glucose control. Overall, the mechanism is positioned as coordinated appetite suppression plus glucose-dependent endocrine effects, with the usual tolerability concern being dose-dependent gastrointestinal symptoms during escalation.
Nausea, vomiting, diarrhea, constipation, abdominal pain
Injection-site reactions (redness/swelling/irritation)
Hypoglycemia risk when combined with insulin/sulfonylureas
Rare: pancreatitis, gallbladder disease, acute kidney injury
Thyroid C-cell tumors seen in rodents (human relevance uncertain)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)